TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness-Based Cognitive Therapy for Suicide Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The following criteria were formulated to recruit a sample at high risk for suicide behavior.~* The subject has experienced a suicidal event during the past 30 days. A suicidal event involves~  * 1) psychiatric hospitalization due to suicidal risk,~ * 2) psychiatric hospitalization if subject was already on the High Risk for Suicide List,~ * 3) suicidal ideation with suicidal intent,~ * 4) suicidal preparatory behaviors, or~ * 5) actual, interrupted, or aborted suicide attempt.~AND~* The subject is on or will be placed on the VA High Risk for Suicide List~  * OR The subject had an actual, interrupted, or aborted attempt in the last year~ * OR In the study clinician's opinion (i.e., Masters or Doctoral level study personnel with formal mental health training) in consultation with the PI, the suicidal event is significant enough to warrant treatment to reduce suicidal risk.~Exclusion Criteria:~* cognitive deficits that decrease the likelihood of benefit from MBCT-S~* severe symptoms of hallucinations or delusions~* disorganized or disruptive behaviors~* medically unstable~* current mindfulness-based psychotherapy or receipt of 2 or more sessions of a mindfulness-based psychotherapy in the last 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mindfulness-Based Cognitive Therapy + Treatment As Usual (Type: ACTIVE_COMPARATOR): Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
- Treatment As Usual (Type: OTHER): VA standard care for suicide prevention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed or recurrent epidermoid cancer of the head and neck~* Requires more than minimal therapy for treatment~* Able to read and write in English~* Willing to use an effective form of birth control throughout the study~Exclusion Criteria:~* Meets MINI criteria for major depression, schizophrenia, or bipolar illness or scores 24 or less~* Suicidal or psychotic~* Current allergy or hypersensitivity to citalopram or other SSRIs~* Treated with monoamine oxidase inhibitors 14 days prior to study entry~* Use of antidepressants within 1 week of study entry~* Pregnant or breastfeeding~* History of an adequate cancer operation, radiation, or chemotherapy within 6 months of study entry~* Diagnosed with melanoma or lymphoma cancer of the head and neck~* Currently participating in another research study involving a therapeutic intervention

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): Participants will receive treatment with escitalopram
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive treatment with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic pancreatic adenocarcinoma confirmed by histology~* Tumor sample available~* Measurable lesion according to RECIST criteria~* Performance status ≥ 1~* Life expectancy \> 3 months~* Hematology: Hb ≥ 9g/dL, neutrophils ≥ 1,500/mm3, platelets ≥ 100,000/mm3~* Renal function: creatinine ≤ 1.5 x ULN~* Hepatic function: total bilirubin ≤ 2.5 x ULN, transaminases ≤ 5 x ULN~* Left ventricular ejection fraction (LVEF) ≥ 50%~* At least a 6-month delay between the end of any previous gemcitabine-based chemotherapy and diagnosis of metastases~* Social security~* Informed consent obtained prior to inclusion.~Exclusion Criteria:~* Non metastatic advanced local disease~* Presence of cerebral metastases or symptomatic leptomeningeal carcinomatosis~* Others cancers except BBC and cervical cancer receiving curative treatment~* No previous treatment by Erlotinib or Trastuzumab~* Known severe hypersensitivity to Erlotinib, Trastuzumab, murine proteins or Gemcitabine~* Presence of significant co-morbidities~* Concomitant treatment with other experimental products or other anticancer therapies~* Breastfeeding or pregnant female, or patient of reproductive age not using adequate contraception~* Legal incapacity or limited legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Gemcitabine - Trastuzumab - Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a life expectancy of at least 12 weeks~* Patients with histologically or cytologically confirmed unresectable (Stage III) or metastatic (Stage IV) melanoma~* Patients who have an ECOG PS of 0, or 1~* Measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST criteria~Exclusion Criteria:~* Primary ocular or mucosal melanoma~* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta \[Noninvasive papillary carcinoma\], Tis \[Carcinoma in situ: flat tumor\] \& T1 \[Tumor invades subepithelial connective tissue\]) or any cancer curatively treated \< 3 years prior to study entry~* History of cardiac disease~* Known history of human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (Type: EXPERIMENTAL): Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m\^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
- Placebo + Dacarbazine (Type: ACTIVE_COMPARATOR): Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m\^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Summary Inclusion Criteria:~* Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence~* Deemed healthy enough to participate by study physician~* Age 18-55~* Right handed~* English-speaking~Summary Exclusion Criteria:~* Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years~* Pregnancy~* MRI contraindications (e.g. metal in head).~The research is conducted in Portland, OR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Extended release naltrexone (Type: EXPERIMENTAL): One dose of intramuscular injection of 380mg extended-release naltrexone.
- Placebo (Type: PLACEBO_COMPARATOR): One dose of intramuscular injection of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Beneficial Bacteria Treatment for Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children ages 7-17 years~2. Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)~3. Moderate or Severe GI problems ( on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items~4. No changes in medications, supplements, diet, therapies, or education in last 3 months, and no intention to change them during clinical trial~5. General good physical health aside from gastrointestinal problems~6. Cognitive Ability to Provide Informed Assent~Exclusion Criteria:~1. Antibiotics in last 6 months~2. Probiotics in last 3 months~3. Single-gene disorder (Fragile X, etc.)~4. Major brain malformation~5. Tube feeding~6. Severe gastrointestinal problems that require immediate treatment (life-threatening)~7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions~8. Severely underweight/malnourished~9. Recent or scheduled surgeries~10. Current participation in other clinical trials

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Oral Group (Type: EXPERIMENTAL): This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
- Rectal Group (Type: EXPERIMENTAL): This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Good general and oral health without any known allergy to commercial dental products or cosmetics~* Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial~* Willingness to use the assigned products according to instructions, availability for appointments, and likelihood of completing the clinical trial~* Dental condition appropriate for inclusion in the trial according to protocol-specified parameters and the professional opinion of the investigator~* Adequate oral hygiene (i.e. brush teeth daily and exhibit no signs of oral neglect~Exclusion Criteria:~* Medical condition or history, or use of drugs or treatments that could possibly compromise the safety of the research subject or the interpretation of results, per protocol or in the opinion of the investigator~* Use of home-care bleaching, whitening products or professional bleaching treatment within a protocol-specified time period~* Use of desensitizing agents within a protocol-specified time period~* Participation in a dental clinical trial involving oral care products within a protocol-specified time period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mouth Rinse (Type: EXPERIMENTAL): Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
- Fluoride Toothpaste (Type: ACTIVE_COMPARATOR): Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
- Potassium Nitrate Toothpaste (Type: ACTIVE_COMPARATOR): Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria~* The current depressive episode must be equal to or greater than 8 weeks in duration~* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.~* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder~* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Phase B (Type: EXPERIMENTAL): Drug: OPC-34712 + ADT~Drug: Placebo + ADT
- Phase A (Type: PLACEBO_COMPARATOR): Intervention: Drug: Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over 18 years of age~* Type 1 diabetes confirmed on the basis of clinical features and a fasting c-peptide \<200 pmol/L~* Severe hypoglycaemic event in the last 12 months requiring third party assistance OR a Gold Score ≥ 4~* Type 1 diabetes for greater than 3 years~* On an intensified multiple dose insulin injection regimen for \> 6 months (MDI)~* Previous type 1 diabetes structured education (either group or 1:1)~Exclusion Criteria:~* Use of CGM or Libre device within the last 6 months (except short periods of diagnostic blinded use under clinic supervision)~* Use of regular paracetamol~* Pregnant or planning pregnancy~* Breastfeeding~* Enrolled in other clinical trials, except at the discretion of the chief investigator~* Have active malignancy or under investigation for malignancy~* Severe visual impairment~* Reduced manual dexterity~* Unable to participate due to other factors, as assessed by the Chief Investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Real time continuous glucose monitoring (Type: ACTIVE_COMPARATOR): Use of Dexcom G5 continuous glucose monitoring
- Flash glucose monitoring (Type: ACTIVE_COMPARATOR): Use of Abbott FreeStyle Libre flash glucose monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pioglitazone on Platelet Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be over 21 years of age and provide written informed consent.~* Normal subjects must have a BMI \<30 and must not have known cardiovascular disease, Diabetes Mellitus (DM), hyperlipidemia, or hypertension. Diabetic subjects must have previously diagnosed DM.~Exclusion Criteria:~* Subjects will be excluded if they have hypersensitivity to aspirin or pioglitazone, or if they are receiving warfarin or heparin therapy, are pregnant, or have congestive heart failure or hepatic function impairment.~* Subjects must not have taken aspirin or other drugs inhibiting platelet function such as Plavix or non-steroidal anti-inflammatory drugs for 7 days.~* Subjects will be excluded if they have a history of renal failure, severe liver disease, myeloproliferative disease or other conditions that impair platelet function.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pioglitazone with or without Aspirin (Type: EXPERIMENTAL): Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed informed consent prior to initiation of any study-specific procedure or treatment. The subject or their legally authorized representative must be able to provide written informed consent and understand the potential risks and benefits from study enrollment and treatment.~2. Male or female subject ≥ 18 years of age.~3. A qualifying episode of CDI as defined by:~   1. ≥ 3 unformed stools per day for 2 consecutive days~  2. A positive C. difficile stool toxin assay.~  3. The requirement of CDI SOC antibiotic therapy (defined as 10 to 21 days of treatment with vancomycin \[125 mg QID\] and/or fidaxomicin \[200 mg BID\]).~  4. An adequate clinical response following SOC antibiotic therapy, defined as (\<3 unformed stools in 24 hours) for 2 or more consecutive days before randomization.~Main Exclusion Criteria:~1. Female subjects who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.~2. Known or suspected toxic megacolon and/or known small bowel ileus.~3. Admitted to or expected to be admitted to an intensive care unit for medical reasons (not just boarding). Note: nursing homes, rehabilitation, assisted living centers and acute care hospitals are acceptable.~4. Absolute neutrophil count of \<500 cells/ml\^3~5. Major gastrointestinal surgery (e.g. significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy), or any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are permitted).~6. History of active inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel disease in the past 3 months.~7. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (subjects on maintenance chemotherapy may only be enrolled after consultation with the study medical monitor).~8. Any history of fecal microbiota transplantation (FMT) within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SER-109 (Type: EXPERIMENTAL): Received oral dose of SER-109
- Placebo (Type: PLACEBO_COMPARATOR): Received matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete